{"id":10659,"date":"2003-02-01T10:36:22","date_gmt":"2003-02-01T10:36:22","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10659"},"modified":"2014-05-28T16:47:00","modified_gmt":"2014-05-28T16:47:00","slug":"bms-submits-new-drug-application-for-investigational-protease-inhibitior-atazanavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10659","title":{"rendered":"BMS submits new drug application for investigational protease inhibitior atazanavir"},"content":{"rendered":"<p><strong>Bristol-Myers Squibb (BMS) has announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for atazanavir, an investigational protease inhibitor under development for the treatment of HIV\/AIDS in combination with other antiretroviral agents.<\/strong><\/p>\n<p>Atazanavir, currently in phase III clinical development, is an azapeptide viral protease inhibitor of HIV-1. It is the first protease inhibitor to be submitted with pharmacokinetic data supporting the potential for once-daily administration. The NDA includes data from more than 2,400 patients enrolled in clinical trials comparing atazanavir to widely prescribed drugs for HIV infection.<\/p>\n<p>Source: Bristol-Myers Squibb Company<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb (BMS) has announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for atazanavir, an investigational protease inhibitor under development for the treatment of HIV\/AIDS in combination with other antiretroviral agents. &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-10659","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10659"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10659\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}